NIT1

Summary

NIT1 (nitrilase 1, HGNC:7828) is a protein-coding gene on chromosome 1q23.3, encoding Deaminated glutathione amidase (Q86X76). Catalyzes the hydrolysis of the amide bond in N-(4-oxoglutarate)-L-cysteinylglycine (deaminated glutathione), a metabolite repair reaction to dispose of the harmful deaminated glutathione.

This gene encodes a member of the nitrilase protein family with homology to bacterial and plant nitrilases, enzymes that cleave nitriles and organic amides to the corresponding carboxylic acids plus ammonia. Multiple transcript variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 4817 — RefSeq curated summary.

At a glance

• Gene–disease (curated): cerebrovascular disorder (Strong, GenCC)
• Clinical variants (ClinVar): 85 total — 3 pathogenic, 1 likely-pathogenic
• Phenotypes (HPO): 30
• Druggable target: yes
• MANE Select transcript: NM_005600

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:7828
Approved symbol	NIT1
Name	nitrilase 1
Location	1q23.3
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000158793
Ensembl biotype	protein_coding
OMIM	604618
Entrez	4817

Gene structure

Transcript identifiers

Ensembl transcripts: 21 — 12 protein_coding_CDS_not_defined, 9 protein_coding

ENST00000368007, ENST00000368008, ENST00000368009, ENST00000392190, ENST00000461376, ENST00000473918, ENST00000477684, ENST00000478277, ENST00000479266, ENST00000479728, ENST00000485594, ENST00000486962, ENST00000491497, ENST00000492411, ENST00000496768, ENST00000496861, ENST00000865250, ENST00000865251, ENST00000935621, ENST00000935622, ENST00000940923

RefSeq mRNA: 4 — MANE Select: NM_005600 NM_001185092, NM_001185093, NM_001185094, NM_005600

CCDS: CCDS1218, CCDS53401, CCDS53402, CCDS53403

Canonical transcript exons

ENST00000368009 — 7 exons

Exon	Start	End
ENSE00001446119	161120499	161121194
ENSE00002229018	161118105	161118178
ENSE00003460133	161119819	161119952
ENSE00003499162	161118786	161118881
ENSE00003536273	161120107	161120232
ENSE00003588701	161119134	161119388
ENSE00003646891	161119509	161119612

Expression profiles

Bgee: expression breadth ubiquitous, 287 present calls, max score 97.32.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 26.5981 / max 188.6881, expressed in 1817 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
6199	26.5981	1817

Top tissues by expression

294 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right adrenal gland cortex	UBERON:0035827	97.32	gold quality
right adrenal gland	UBERON:0001233	97.26	gold quality
left adrenal gland	UBERON:0001234	96.62	gold quality
left adrenal gland cortex	UBERON:0035825	96.51	gold quality
adrenal cortex	UBERON:0001235	96.37	gold quality
mucosa of transverse colon	UBERON:0004991	96.36	gold quality
right lobe of liver	UBERON:0001114	95.96	gold quality
adrenal gland	UBERON:0002369	95.92	gold quality
small intestine Peyer’s patch	UBERON:0003454	94.37	gold quality
transverse colon	UBERON:0001157	94.32	gold quality
duodenum	UBERON:0002114	94.18	gold quality
small intestine	UBERON:0002108	94.14	gold quality
rectum	UBERON:0001052	93.93	gold quality
adenohypophysis	UBERON:0002196	93.93	gold quality
granulocyte	CL:0000094	93.85	gold quality
adrenal tissue	UBERON:0018303	93.83	gold quality
liver	UBERON:0002107	93.78	gold quality
body of pancreas	UBERON:0001150	93.77	gold quality
jejunal mucosa	UBERON:0000399	93.74	gold quality
metanephros cortex	UBERON:0010533	93.47	gold quality
right lobe of thyroid gland	UBERON:0001119	93.28	gold quality
left lobe of thyroid gland	UBERON:0001120	93.23	gold quality
pituitary gland	UBERON:0000007	93.11	gold quality
adult mammalian kidney	UBERON:0000082	92.76	gold quality
descending thoracic aorta	UBERON:0002345	92.56	gold quality
thyroid gland	UBERON:0002046	92.55	gold quality
right uterine tube	UBERON:0001302	92.54	gold quality
apex of heart	UBERON:0002098	92.52	gold quality
right coronary artery	UBERON:0001625	92.46	gold quality
left coronary artery	UBERON:0001626	92.43	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.08
E-MTAB-6386	no	353.66

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): MYC

miRNA regulators (miRDB)

42 targeting NIT1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-7162-3P	99.89	68.16	1682
HSA-MIR-1299	99.77	71.24	2389
HSA-MIR-4320	99.75	65.80	793
HSA-MIR-378G	99.71	64.90	1106
HSA-MIR-33A-3P	99.70	70.27	3362
HSA-MIR-3059-5P	99.70	69.93	2491
HSA-MIR-875-3P	99.63	69.47	2548
HSA-MIR-4663	99.62	65.33	957
HSA-MIR-5003-5P	99.61	69.13	1624
HSA-MIR-516B-5P	99.56	66.33	1495
HSA-MIR-6716-5P	99.56	68.62	1244
HSA-MIR-4276	99.56	67.66	2514
HSA-MIR-4437	99.52	65.29	1266
HSA-MIR-203A-3P	99.49	70.56	2806
HSA-MIR-6727-3P	99.49	65.92	1333
HSA-MIR-4722-3P	99.35	65.22	1099
HSA-MIR-6505-3P	99.34	67.39	1071
HSA-MIR-5584-3P	99.23	68.79	1351
HSA-MIR-8065	99.19	70.38	1289
HSA-MIR-10524-5P	99.05	66.08	963
HSA-MIR-939-3P	98.97	65.07	2347
HSA-MIR-3124-3P	98.87	68.95	2123
HSA-MIR-6829-5P	98.86	65.12	1480
HSA-MIR-4755-3P	98.77	65.59	1915
HSA-MIR-1301-3P	98.64	68.27	1071
HSA-MIR-5047	98.64	68.62	1035
HSA-MIR-660-3P	98.14	66.04	1434
HSA-MIR-6881-3P	98.04	68.24	1777
HSA-MIR-4303	98.01	68.13	2304
HSA-MIR-146B-3P	97.83	65.29	782

Literature-anchored findings (GeneRIF, showing 6)

• Nit1 and Fhit share tumor suppressor signaling pathways, while localization of the NIT1 gene at a stable chromosome site explains the paucity of gene alterations and in frequent loss of expression of the NIT1 gene in human malignancies. (PMID:16864578)
• Human NIT1/2 are not involved in the metabolism of vildagliptin. (PMID:25008847)
• Data show that cisplatin response was enhanced in human lung cancer cells when Nit1 was knocked down and mice Nit1-/-:KrasG12D/+ tumors showed increased sensitivity to cisplatin in vivo. (PMID:26967383)
• NIT1 suppresses colorectal cancer cell proliferation through a positive feedback loop between NIT1 and activation of the TGFbeta-Smad2/3 signalling pathway. (PMID:29449642)
• The Rosetta Stone Hypothesis-Based Interaction of the Tumor Suppressor Proteins Nit1 and Fhit. (PMID:36766695)
• Bi-allelic NIT1 variants cause a brain small vessel disease characterized by movement disorders, massively dilated perivascular spaces, and intracerebral hemorrhage. (PMID:38430071)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	nit1	ENSDARG00000070116
mus_musculus	Nit1	ENSMUSG00000013997
rattus_norvegicus	Nit1	ENSRNOG00000003881
drosophila_melanogaster	NitFhit	FBGN0024945
caenorhabditis_elegans		WBGENE00003594

Paralogs (2): UPB1 (ENSG00000100024), NIT2 (ENSG00000114021)

Protein

Protein identifiers

Deaminated glutathione amidase — Q86X76 (reviewed: Q86X76)

Alternative names: Nitrilase homolog 1

All UniProt accessions (1): Q86X76

UniProt curated annotations — full annotation on UniProt →

Function. Catalyzes the hydrolysis of the amide bond in N-(4-oxoglutarate)-L-cysteinylglycine (deaminated glutathione), a metabolite repair reaction to dispose of the harmful deaminated glutathione. Plays a role in cell growth and apoptosis: loss of expression promotes cell growth, resistance to DNA damage stress and increased incidence to NMBA-induced tumors. Has tumor suppressor properties that enhances the apoptotic responsiveness in cancer cells; this effect is additive to the tumor suppressor activity of FHIT. It is also a negative regulator of primary T-cells.

Subcellular location. Mitochondrion Cytoplasm.

Tissue specificity. Detected in heart, brain, placenta, liver, skeletal muscle, kidney and pancreas.

Disease relevance. Brain small vessel disease 4 (BSVD4) [MIM:621313] An autosomal recessive, adult-onset form of brain small vessel disease, a cerebrovascular disorder with variable manifestations reflecting the location and severity of the vascular defect. BSVD4 patients manifest neurologic symptoms and deficits due to ischemic and/or hemorrhagic events in the brain. Clinical features include progressive movement disorders, such as dystonia, chorea, bradykinesia, tremor as well as gait disturbance and dysarthria, and cognitive decline. Some patients may have psychiatric features. Neuroimaging shows dilated perivascular spaces and cavitating lesions, especially prominent in the basal ganglia and thalamus. The disease is caused by variants affecting the gene represented in this entry.

Miscellaneous. According to Rosetta Stone theory, the existence of a fusion protein in one genome predicts that the separate polypeptides expressed in other organisms function in the same cellular or biochemical pathway. In Drosophila melanogaster and Caenorhabditis elegans, NitFhit is a fusion protein composed of a C-terminal Fhit domain and a domain related to plant and bacterial nitrilase. Major isoform. Based on a naturally occurring readthrough transcript which produces a NIT1-DEDD fusion protein. The last 4 amino acids of this isoform (PVSS) are encoded by the last DEDD exon.

Similarity. Belongs to the carbon-nitrogen hydrolase superfamily. NIT1/NIT2 family.

Isoforms (5)

UniProt ID	Names	Canonical?
Q86X76-1	2	yes
Q86X76-2	1, 3
Q86X76-3	4
Q86X76-4	5
Q86X76-5	6

RefSeq proteins (4): NP_001172021, NP_001172022, NP_001172023, NP_005591* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001110	UPF0012_CS	Conserved_site
IPR003010	C-N_Hydrolase	Domain
IPR036526	C-N_Hydrolase_sf	Homologous_superfamily
IPR045254	Nit1/2_C-N_Hydrolase	Domain

Pfam: PF00795

Catalyzed reactions (Rhea), 1 shown:

• N-(4-oxoglutaryl)-L-cysteinylglycine + H2O = L-cysteinylglycine + 2-oxoglutarate (RHEA:54532)

UniProt features (14 total): splice variant 6, active site 3, transit peptide 1, chain 1, sequence variant 1, sequence conflict 1, domain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q86X76-F1	88.57	0.82

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (3): 86 (proton acceptor); 161 (proton donor); 203 (nucleophile)

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 120 (showing top): DARWICHE_SKIN_TUMOR_PROMOTER_DN, DARWICHE_PAPILLOMA_RISK_LOW_DN, DARWICHE_PAPILLOMA_RISK_HIGH_DN, DARWICHE_SQUAMOUS_CELL_CARCINOMA_DN, BROWNE_HCMV_INFECTION_48HR_DN, GOBP_AMIDE_METABOLIC_PROCESS, USF_01, BROWNE_HCMV_INFECTION_14HR_DN, DOUGLAS_BMI1_TARGETS_DN, USF_02, GTGACTT_MIR224, DANG_BOUND_BY_MYC, USF2_Q6, MYC_Q2, MYCMAX_03

GO Biological Process (1): obsolete amide catabolic process (GO:0043605)

GO Molecular Function (3): deaminated glutathione amidase activity (GO:0110050), hydrolase activity (GO:0016787), hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in linear amides (GO:0016811)

GO Cellular Component (3): nucleus (GO:0005634), cytoplasm (GO:0005737), mitochondrion (GO:0005739)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
intracellular membrane-bounded organelle	2
hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in linear amides	1
catalytic activity	1
hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds	1
intracellular anatomical structure	1
cellular anatomical structure	1
cytoplasm	1

Protein interactions and networks

STRING

1546 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
NIT1	DEDD	O75618	579
NIT1	INS	P01308	564
NIT1	FFAR1	O14842	419
NIT1	GPR119	Q8TDV5	419
NIT1	RPL23	P23131	414
NIT1	FHIT	P49789	405
NIT1	SLC25A23	Q9BV35	400
NIT1	GCG	P01275	389
NIT1	POLA2	Q14181	386
NIT1	TDP2	O95551	371
NIT1	AGPAT1	Q99943	370
NIT1	RPL12	P30050	368
NIT1	OXCT1	P55809	364
NIT1	SLC27A4	Q6P1M0	356
NIT1	C3orf38	Q5JPI3	350

IntAct

24 interactions, top by confidence:

A	B	Type	Score
SLC31A1	C2orf72	psi-mi:“MI:0914”(association)	0.530
LRRC57	NIT1	psi-mi:“MI:0915”(physical association)	0.400
NIT1	ZFYVE9	psi-mi:“MI:0915”(physical association)	0.370
SIRT4	VWA8	psi-mi:“MI:0914”(association)	0.350
NDUFA11	NDUFS8	psi-mi:“MI:0914”(association)	0.350
NIT1	NDUFS6	psi-mi:“MI:0914”(association)	0.350
SDHAF4	GPX4	psi-mi:“MI:0914”(association)	0.350
NIT1	PMPCB	psi-mi:“MI:0914”(association)	0.350
ZNRD2	KRBA1	psi-mi:“MI:0914”(association)	0.350
NIT1	NUDT19	psi-mi:“MI:0914”(association)	0.350
HOXC5	PDLIM1	psi-mi:“MI:0914”(association)	0.350
ISOC2	GTPBP1	psi-mi:“MI:0914”(association)	0.350
CAMK2A	SMCHD1	psi-mi:“MI:0914”(association)	0.350
SHARPIN	ZNF609	psi-mi:“MI:0914”(association)	0.350
RTP2	GPAA1	psi-mi:“MI:0914”(association)	0.350
IFT74	ZC3HAV1	psi-mi:“MI:0914”(association)	0.350
PDAP1	NIT1	psi-mi:“MI:0914”(association)	0.350
FGFBP2	RAB4A	psi-mi:“MI:0914”(association)	0.350
SMPD2	A2ML1	psi-mi:“MI:0914”(association)	0.350
NIT1	XRCC6	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (88): CUX1 (Co-fractionation), NIT1 (Co-fractionation), NIT1 (Co-fractionation), NIT1 (Co-fractionation), NIT1 (Co-fractionation), NIT1 (Co-fractionation), NIT1 (Co-fractionation), NIT1 (Co-fractionation), NIT1 (Co-fractionation), PSMG4 (Co-fractionation), NIT1 (Affinity Capture-MS), NIT1 (Affinity Capture-MS), NIT1 (Affinity Capture-MS), SLC25A27 (Affinity Capture-MS), IBA57 (Affinity Capture-MS)

ESM2 similar proteins: A0MTA1, A1YES6, A1YFZ3, A2T6Y4, A2T7I6, A5WVX1, B4FAT0, O54747, O94903, P0A2X3, P0A2X4, P13051, P23196, P26882, P27695, P28339, P28340, P28352, P36776, P43138, P52431, P97283, P97931, Q08752, Q08DF7, Q0J705, Q0V9S0, Q16775, Q32LH4, Q3B7M2, Q3T0G5, Q3TIU4, Q4P1V1, Q4R5U5, Q4R6C1, Q59HJ6, Q5R4Z1, Q5XIP6, Q5ZI23, Q653S9

Diamond homologs: A0A140NCB4, O31664, O59829, O76463, O94660, P0DP63, P0DP64, P0DP66, P0DP67, P0DP68, P47016, P55175, P55178, P58054, P9WJ00, P9WJ01, Q32LH4, Q557J5, Q7TQ94, Q86X76, Q8VDK1, Q93NG1, A0A140NDS5, P0DP65, P55176, P55177, Q47679, Q8RUF8, O76464, Q10166, Q28IE5, Q2T9R6, Q4VBV9, Q54JM9, Q5R4L6, Q6INI7, Q6IR61, Q75SP7, Q94JV5, Q9JHW2

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 33 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Aerobic respiration and respiratory electron transport	5	21.1×	4e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

85 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	3
Likely pathogenic	1
Uncertain significance	70
Likely benign	2
Benign	1

Top pathogenic / likely-pathogenic (4)

Variant ID	HGVS	Classification
4076955	NM_005600.3(NIT1):c.198_199del (p.Cys67_Ala68insTer)	Pathogenic
4076956	NIT1, 457G-A	Pathogenic
4076957	NIT1, 1-BP DUP, 670A	Pathogenic
3256938	NM_005600.3(NIT1):c.591+2T>G	Likely pathogenic

SpliceAI

1600 predictions. Top by Δscore:

Variant	Effect	Δscore
1:161119366:G:GT	donor_gain	1.0000
1:161120105:A:AG	acceptor_gain	1.0000
1:161120105:A:T	acceptor_loss	1.0000
1:161120105:AGATT:A	acceptor_gain	1.0000
1:161120106:G:GT	acceptor_gain	1.0000
1:161120106:GA:G	acceptor_gain	1.0000
1:161120106:GAT:G	acceptor_gain	1.0000
1:161120106:GATT:G	acceptor_gain	1.0000
1:161120106:GATTG:G	acceptor_gain	1.0000
1:161120228:GGGAG:G	donor_gain	1.0000
1:161120229:GGAG:G	donor_gain	1.0000
1:161120229:GGAGG:G	donor_gain	1.0000
1:161120230:GAGG:G	donor_gain	1.0000
1:161120231:AGGT:A	donor_loss	1.0000
1:161120232:GGTAA:G	donor_loss	1.0000
1:161120233:G:A	donor_loss	1.0000
1:161120234:T:A	donor_loss	1.0000
1:161122521:TGT:T	acceptor_gain	1.0000
1:161122522:GTC:G	acceptor_loss	1.0000
1:161122523:TCTG:T	acceptor_loss	1.0000
1:161122524:C:CC	acceptor_gain	1.0000
1:161122527:T:TC	acceptor_gain	1.0000
1:161122534:C:CT	acceptor_gain	1.0000
1:161122535:A:T	acceptor_gain	1.0000
1:161123068:T:TA	donor_gain	1.0000
1:161123833:TCTCA:T	donor_loss	1.0000
1:161123834:CTCAC:C	donor_loss	1.0000
1:161123835:TCA:T	donor_loss	1.0000
1:161123836:CA:C	donor_loss	1.0000
1:161123838:C:CA	donor_loss	1.0000

AlphaMissense

2087 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:161120137:T:C	F208L	0.996
1:161120139:C:A	F208L	0.996
1:161120139:C:G	F208L	0.996
1:161120200:T:C	F229L	0.994
1:161120202:T:A	F229L	0.994
1:161120202:T:G	F229L	0.994
1:161119844:G:C	K161N	0.993
1:161119844:G:T	K161N	0.993
1:161120595:A:C	S272R	0.993
1:161120597:C:A	S272R	0.993
1:161120597:C:G	S272R	0.993
1:161120129:A:T	D205V	0.991
1:161120180:T:A	I222K	0.989
1:161120518:C:A	A246D	0.989
1:161119843:A:C	K161T	0.987
1:161120128:G:C	D205H	0.987
1:161120229:G:C	W238C	0.987
1:161120229:G:T	W238C	0.987
1:161120515:G:C	R245P	0.987
1:161120616:G:A	G279R	0.987
1:161120616:G:C	G279R	0.987
1:161120128:G:T	D205Y	0.986
1:161120129:A:C	D205A	0.986
1:161120138:T:C	F208S	0.986
1:161119385:C:A	A117D	0.985
1:161120517:G:C	A246P	0.985
1:161120617:G:T	G279V	0.985
1:161119184:C:A	A50D	0.984
1:161120545:C:A	A255E	0.984
1:161119289:C:A	P85H	0.983

dbSNP variants (sampled 300 via entrez): RS1000050394 (1:161119877 G>A), RS1000893680 (1:161121235 C>A,T), RS1001560087 (1:161124615 G>A), RS1001596000 (1:161124893 C>T), RS1001725631 (1:161124025 A>G), RS1001895572 (1:161122829 C>T), RS1001961229 (1:161116475 C>T), RS1001988211 (1:161124519 C>T), RS1002479018 (1:161116776 T>C), RS1002635454 (1:161118985 G>T), RS1003161207 (1:161119384 G>A), RS1003934925 (1:161119356 G>A), RS1004003101 (1:161120806 C>A,G,T), RS1004474874 (1:161118902 C>T), RS1004517170 (1:161124712 A>G)

Disease associations

OMIM: gene MIM:604618 | disease phenotypes: MIM:621313

GenCC curated gene-disease

Disease	Classification	Inheritance
cerebrovascular disorder	Strong	Autosomal recessive

Mondo (2): brain small vessel disease 4 (MONDO:0979873), cerebrovascular disorder (MONDO:0011057)

Orphanet (0):

HPO phenotypes

30 total (30 of 30 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000709	Psychosis
HP:0000716	Depression
HP:0001256	Mild intellectual disability
HP:0001257	Spasticity
HP:0001259	Coma
HP:0001260	Dysarthria
HP:0001269	Hemiparesis
HP:0001279	Syncope
HP:0001288	Gait disturbance
HP:0001297	Stroke
HP:0001332	Dystonia
HP:0001337	Tremor
HP:0001342	Cerebral hemorrhage
HP:0002067	Bradykinesia
HP:0002072	Chorea
HP:0002140	Ischemic stroke
HP:0002197	Generalized-onset seizure
HP:0002353	EEG abnormality
HP:0002445	Tetraplegia
HP:0003596	Middle age onset
HP:0006799	Basal ganglia cysts
HP:0011462	Young adult onset
HP:0011463	Childhood onset
HP:0011942	Increased urinary sulfite level
HP:0012378	Fatigue
HP:0012520	Dilation of Virchow-Robin spaces
HP:0032325	Lacunar stroke
HP:0100543	Cognitive impairment
HP:0100753	Schizophrenia

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D002561	Cerebrovascular Disorders	C10.228.140.300; C14.907.253

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4295883 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

53 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	affects cotreatment, decreases expression, increases abundance, increases expression	4
Smoke	decreases expression	2
aristolochic acid I	decreases expression	1
bisphenol F	increases expression	1
2,4,6-tribromophenol	decreases expression	1
bufotalin	decreases expression	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
alpha-pinene	affects cotreatment, increases expression, increases abundance	1
decabromobiphenyl ether	decreases expression	1
trichostatin A	affects expression	1
beta-lapachone	increases expression	1
tetrabromobisphenol A	increases expression	1
potassium chromate(VI)	decreases expression, affects cotreatment	1
methacrylaldehyde	affects cotreatment, increases expression, increases abundance	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
fenpyroximate	decreases expression	1
4-chloro-N-((4-(1,1-dimethylethyl)phenyl)methyl)-3-ethyl-1-methyl-1H-pyrazole-5-carboxamide	decreases expression	1
ICG 001	decreases expression	1
bisphenol B	increases expression	1
abrine	increases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	decreases expression	1
pyrachlostrobin	decreases expression	1
pentabrominated diphenyl ether 100	decreases expression	1
hexabrominated diphenyl ether 153	decreases expression	1
jinfukang	increases expression	1
picoxystrobin	decreases expression	1
NSC 689534	affects binding, increases expression	1

ChEMBL screening assays

2 unique, capped per target: 2 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4118728	Binding	Binding affinity to NIT1 in human NCI-H23 cells at 1 uM by mass spectrometry based pull down assay	Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors. — Bioorg Med Chem

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00004727	PHASE4	COMPLETED	Antiplatelet Therapy to Prevent Stroke in African Americans
NCT00029172	PHASE4	COMPLETED	Treatment for Post-Stroke Depression
NCT00079638	PHASE4	COMPLETED	Comparative Efficacy Evaluation of Lipids When Treated With Niaspan & Statin or Other Lipid-Modifying Therapies-COMPELL
NCT00101543	PHASE4	COMPLETED	Gait Training For Acute Stroke: Functional Neuromuscular Stimulation (FNS) and Weight Supported Treadmill Training
NCT00102869	PHASE4	COMPLETED	Dopaminergic Enhancement of Learning and Memory in Aphasia
NCT00106886	PHASE4	UNKNOWN	HOPE-2 Study (Heart Outcomes Prevention Evaluation-2 Study)
NCT00108706	PHASE4	UNKNOWN	Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST)
NCT00126087	PHASE4	TERMINATED	Potentiation of Procedural Motor Learning in Health and Disease
NCT00130039	PHASE4	COMPLETED	Trial of Cilostazol in Symptomatic Intracranial Arterial Stenosis II
NCT00149227	PHASE4	COMPLETED	Add-on Effects of Valsartan on Morbi- Mortality (KYOTO HEART Study)
NCT00153062	PHASE4	COMPLETED	PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes
NCT00153946	PHASE4	COMPLETED	Edaravone and Argatroban Stroke Therapy Study for Acute Ischemic Stroke
NCT00163150	PHASE4	COMPLETED	Vasomotor Reactivity In Cerebral Small Vessel Disease And New Approach To Treat Lacunar Stroke
NCT00177424	PHASE4	TERMINATED	Sertraline for Preventing Post-stroke Depression and Improving Rehabilitation Outcomes
NCT00178646	PHASE4	COMPLETED	Comparative Efficacy of Three Preparations of Botox-A in Treating Spasticity
NCT00196690	PHASE4	COMPLETED	Donepezil in Chronic Poststroke Aphasia: a Randomized Controlled Trial
NCT00196703	PHASE4	UNKNOWN	Memantine and Constraint-Induced Language Therapy in Chronic Poststroke Aphasia:A Randomized Controlled Trial
NCT00200356	PHASE4	COMPLETED	Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic Stroke
NCT00216411	PHASE4	COMPLETED	Effects on Quality of Life Following Dysport Treatment in Post-stroke Spasticity of the Arm
NCT00227994	PHASE4	COMPLETED	Acetylcholinesterase Inhibitors to Improve Cognitive Function and Overall Rehabilitation After a Stroke
NCT00234065	PHASE4	COMPLETED	Post-marketing Study of Cilostazol (Cilostazol Stroke Prevention Study 2)
NCT00234546	PHASE4	COMPLETED	Asian Botulinum Clinical Trial Designed for Early Stroke Spasticity
NCT00247533	PHASE4	UNKNOWN	Cerebral Artery Stenosis, Coronary Artery Disease and Arrhythmia
NCT00263393	PHASE4	COMPLETED	Rural Andhra Pradesh Cardiovascular Prevention Study (RAPCAPS)
NCT00272454	PHASE4	COMPLETED	Cilostazol in Acute Ischemic Stroke Treatment (CAIST)
NCT00279149	PHASE4	COMPLETED	TRUST-tPA: Therapeutic Trial Evaluating Efficacy of Telemedicine (TELESTROKE) of Patients With Acute Stroke
NCT00287508	PHASE4	COMPLETED	Emboshield® and Xact® Post Approval Carotid Stent Trial (The EXACT Study)
NCT00327418	PHASE4	COMPLETED	CARDS Is Designed To Show If Lowering Cholesterol With Atorvastatin In Type 2 Diabetics Without CV Disease Reduces The Risk Of CV Events
NCT00327691	PHASE4	COMPLETED	A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels
NCT00351806	PHASE4	COMPLETED	AISTCM-Outcome Measurement of Acute Ischemic Stroke With Traditional Chinese Medicine
NCT00386191	PHASE4	COMPLETED	Safety and Efficacy of Clopidogrel for Cerebral Infarction Treatment
NCT00396058	PHASE4	TERMINATED	The Effect of Methylphenidate on Motor Learning in Stroke Patients
NCT00412867	PHASE4	COMPLETED	Post-marketing Clinical Study of Alteplase for Acute Ischemic Stroke （Japan Alteplase Clinical Trial Ⅱ：J-ACT Ⅱ）
NCT00442325	PHASE4	COMPLETED	Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets
NCT00442845	PHASE4	COMPLETED	Establish The Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets (ACTFAST)
NCT00446641	PHASE4	COMPLETED	Overcome Biochemical Aspirin Resistance Through Cilostazol Combination
NCT00468923	PHASE4	COMPLETED	Heart Outcomes Prevention Evaluation-3
NCT00548223	PHASE4	COMPLETED	The Secondary Prevention Trial for Ischemic Stroke With DengzhanShengmai Capsule
NCT00552916	PHASE4	UNKNOWN	Functional Electrical Stimulation (FES) Assisted Walking: Enhancement of Walking Function After Stroke
NCT00559988	PHASE4	TERMINATED	Combined Use of BIOTRONIK Home Monitoring and Predefined Anticoagulation to Reduce Stroke Risk